• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 20-F filed by Gelteq Limited

    10/31/24 4:35:03 PM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GELS alert in real time by email
    NT 20-F 1 ea0219465-nt20f_gelteq.htm NOTIFICATION OF LATE FILING

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Check One):  ☐ Form 10-K  ☒ Form 20-F  ☐ Form 11-K  ☐ Form 10-Q  ☐ Form 10-D  ☐ Form N-CEN  ☐  Form N-CSR

     

    For Period Ended: June 30, 2024

     

    ☐Transition Report on Form 10-K
    ☐Transition Report on Form 20-F
    ☐Transition Report on Form 11-K
    ☐Transition Report on Form 10-Q

     

    For the Transition Period Ended: _____________________________________

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

     

    NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS VERIFIED
    ANY INFORMATION CONTAINED HEREIN.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I -- REGISTRANT INFORMATION

     

    Full Name of Registrant: Gelteq Limited
    Former Name if Applicable: N/A
    Address of Principal Executive Office
    (Street and Number):
    Level 4, 100 Albert Road
    City, State and Zip Code: South Melbourne VIC, 3025, Australia

      

    PART II - RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed (Check box if appropriate)

     

      (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
      (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

     

     

    PART III -- NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    The Registrant is unable to file its Form 20-F for the fiscal year ended June 30, 2024 within the prescribed time period without unreasonable effort or expense because additional time is needed to finalize the financial statements for the fiscal year ended June 30, 2024. The Registrant anticipates that it will file its Form 20-F within the fifteen-day grace period provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

     

    PART IV --OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification:

     

    Nathan J. Givoni

     

    +61

     

    3 9087 3990

    (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

     

    ☒ Yes  ☐ No

     

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     

    ☐ Yes ☒ No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    2

      

      Gelteq Limited  
      (Name of Registrant as Specified in Charter)  

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: October 31, 2024 By: /s/ Nathan J. Givoni
        Nathan J. Givoni
        Chief Executive Officer

     

    3

     

     

     

     

     

    Get the next $GELS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GELS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GELS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership

    MELBOURNE, Australia and LAS VEGAS, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq") and Healthy Extracts™ Inc. ("Healthy Extracts") today announced the signing of a Memorandum of Understanding ("MoU") formalising a strategic partnership designed to accelerate the commercial rollout of next-generation gel-based nutraceutical products. The collaboration builds on Healthy Extracts' prior purchases of Gelteq-formulated products and marks the first phase of a long-term plan to bring Gelteq's proprietary gel delivery technology to large-scale US manufacturing and global distribution. Under the MoU, Healthy Extracts will leverage its established US-based nutritional manufacturing cap

    2/11/26 8:45:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gelteq Announces Positive Preclinical Results Showing Increased Medicinal Cannabinoid Absorption Using Its Oral Gel Delivery Platform

    MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company"), a clinical and science-based developer of advanced gel-based oral delivery systems, today announced positive results from a recently completed preclinical study which evaluated medicinal cannabinoids delivery through the Company's proprietary oral gel platform. The findings demonstrate that Gelteq's platform significantly enhances the absorption and bioavailability of cannabidiol ("CBD") compared to an existing FDA approved oil-based product. The preliminary results reinforces our platform's potential to change how medicinal cannabis is delivered and experienced by patients. Despite having

    1/13/26 9:00:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gelteq Furthers Asia Presence Through Partnership with Hong Kong Flag Football Program

    MELBOURNE, Australia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company"), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced a new partnership with the Hong Kong Flag Football Program. The partnership will integrate Gelteq's advanced hydration and sports performance formulations into the training and competition programs of the region's men's, women's, and youth national teams. The initiative underscores the increasing interest in high-performance programs throughout the region and builds on the recently announced China-focused sales agreement with Shenzhen Mana Health Management Co. Ltd., which includes minimu

    12/16/25 9:05:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GELS
    SEC Filings

    View All

    SEC Form 6-K filed by Gelteq Limited

    6-K - Gelteq Ltd (0001920092) (Filer)

    12/9/25 3:19:42 PM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 20-F filed by Gelteq Limited

    NT 20-F - Gelteq Ltd (0001920092) (Filer)

    11/3/25 5:00:53 PM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Gelteq Limited

    EFFECT - Gelteq Ltd (0001920092) (Filer)

    9/2/25 12:15:18 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GELS
    Financials

    Live finance-specific insights

    View All

    Gelteq Announces Largest U.S. Customer Increases Initial Order by 50% to Meet Growing Market Demand

    NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces its largest U.S. customer, Healthy Extracts (OTCQB:HYEX), has increased its initial purchase order of Gelteq collagen and Mynus sugar blocker gels by 50%, citing high demand and popularity of the products. Healthy Extracts' platform acquires, develops, patents, markets, and distributes plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar n

    12/2/24 8:30:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GELS
    Leadership Updates

    Live Leadership Updates

    View All

    Gelteq Appoints Matthew Jones as Head of Sports Performance

    NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today the appointment of Matthew Jones as Head of Sports Performance. He will oversee the growth, outreach, and customer strategy of Gelteq's sports vertical. "The sports industry is one of a number of key areas that Gelteq's unique formulation can pose a significant improvement to nutrient delivery over traditional methods," said Nathan Givoni, Co-Founder and CEO of Gelteq. "Matthew's pedigree aligns perfectly for this position with his global experie

    1/24/25 8:00:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel Technology

    NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today the appointment of Dr. Paul Wynne as its Chief Scientific Officer ("CSO").  Gelteq co-founder and CEO Nathan Givoni stated, "We believe Dr. Wynne's distinguished record and expertise in formulation science and drug delivery systems will be instrumental in driving the next phase of Gelteq's product pipeline. Recognized for his collaborative approach and ability to coordinate high-performing teams that drive scientific excellence, Dr. Wynne's ped

    12/19/24 8:30:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gelteq Expands Operations in United States with Appointment of Adam Bendell as President of U.S. Operations to Scale Domestic Business

    NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ:GELS) ("Gelteq" or the "Company"), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, announced today that it has expanded its operations in the United States with the appointment of Adam Bendell as President of U.S. Operations.   Gelteq Co-Founder and CEO Nathan Givoni stated, "The appointment of a dedicated U.S.-based President is a critical step in the execution of our growth strategy as we look to scale our operations in the U.S. market. Adam brings not only a wealth of exper

    11/12/24 9:00:00 AM ET
    $GELS
    Biotechnology: Pharmaceutical Preparations
    Health Care